Episode
Pfizer’s Monthly Shot Could Shake Up Weight Loss Market
- Published
- Jun 12, 2026
- Duration seconds
- 115
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/pfizer-s-monthly-shot-could-shake-up-weight-loss-market/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/pfizer-s-monthly-shot-could-shake-up-weight-loss-market.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Pfizer is poised to disrupt the booming weight-loss drug market with berobenatide, a once-monthly injection that could outshine weekly shots from Novo Nordisk and Eli Lilly—offering patients greater convenience and potentially better long-term adherence. With the market projected to hit $150 billion by 2035, Pfizer’s multi-trial approach for both weight loss and type 2 diabetes signals serious intent. While current competitors may still edge ahead in early results, Pfizer’s focus on accessibility could shift the game—and force investors to watch closely as the race for dominance heats up. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/d7c155417b83aef1